Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, has announced the pricing of a US$100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or pre-funded warrants in lieu thereof), before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on October 4, 2023, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents Vistagen in the offering with a capital markets team led by Chicago partners Christopher Lueking and Scott Westhoff, with associates KC Sands, Omeed Valipour, and Claudia Wang. Advice was also provided on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards and Washington, D.C. counsel Monica Groat and Chad Jennings; and on healthcare matters by Bay Area partner Betty Pang.